- Catalyst Pharmaceutical (NASDAQ:CPRX) rallies 15% premarket.
- The company says a jointly funded study with BioMarin (BMRN) to examine the cardiac safety of Firdapse hit its primary endpoint.
- "At and above therapeutic levels, there was no effect of Firdapse on heart rate or cardiac depolarization," CPRX says.
- The company hopes the results "will continue to work toward making Firdapse available to patients in the U.S." (PR)
Catalyst Pharma rises on positive outcome in Firdapse cardiac safety trial
Recommended For You
About CPRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CPRX | - | - |
Catalyst Pharmaceuticals, Inc. |